PCM
CLVS

Penserra Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Penserra Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,705
Closed -$12K – 1623
2021
Q3 		$12K Buy
2,705
+325
+14% +$1.56K ﹤0.01% 1339
2021
Q2 		$13K Buy
2,380
+15
+0.6% +$88 ﹤0.01% 1258
2021
Q1 		$16K Buy
2,365
+340
+17% +$2.28K ﹤0.01% 992
2020
Q4 		$9K Buy
+2,025
New +$10.2K ﹤0.01% 943

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Penserra Capital Management's CLVS Position: Q4 2021 in Review

Penserra Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2021, closing a stake of 2,705 shares — an estimated $12K sold.

Penserra Capital Management first reported a position in CLVS in Q4 2020 and held it in 4 quarters. The position peaked at $16K in Q1 2021. 153 funds tracked by Wall St. Rank hold CLVS as of Q4 2021.

  • Penserra Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 2,705 Clovis Oncology, Inc. shares in Q4 2021, an estimated $12K.
  • Penserra Capital Management first reported a position in Clovis Oncology, Inc. in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Clovis Oncology, Inc. position peaked at $16K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.